Translational Development Acquisition Corp.
Business
Translational Development Acquisition Corp. is a blank check company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It offers units consisting of Class A ordinary shares and redeemable warrants issued in an IPO and related private placement, and maintains proceeds in a U.S.-based trust account. Its operations are organized around identifying, structuring and consummating an initial business combination and managing related shareholder redemption and trust-account processes. It sources targets through relationships with venture capital, growth equity, investment banks, company executives and other intermediaries.
Summary from filing dated 2025-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| General and administrative costs | 944,538 | 196,358 | — | |
| Loss from operations | −944,538 | −196,358 | −485,550 | |
| Dividends earned on marketable securities held in Trust Account | 7 | 125,346 | — | |
| Total other income | 7 | 125,346 | — | |
| Net income (loss) | 6 | −71,012 | −485,550 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash | 29,787 | 438,174 | 2,021 | — | |
| Prepaid expenses | 9,678 | 212,059 | — | — | |
| Total Current Assets | 39,465 | 650,233 | 2,021 | — | |
| Marketable securities held in Trust Account | 182 | 174 | 0 | — | |
| TOTAL ASSETS | 182 | 175 | 2,021 | — | |
| Accounts payable and accrued expenses | 162,311 | 16,189 | — | — | |
| Due to Sponsor | 106,762 | 2,000 | — | — | |
| Promissory note - related party | 200,000 | — | 347,500 | — | |
| Accrued offering costs | 75,000 | 192,114 | 160,927 | — | |
| Total Current Liabilities | 544,073 | 210,303 | 509,679 | — | |
| Deferred underwriting fee | 6 | 6 | — | — | |
| TOTAL LIABILITIES | 7 | 6 | 509,679 | — | |
| Commitments and Contingencies (Note 6) | — | — | — | — | |
| Accumulated deficit | −7 | −6 | −532,658 | — | |
| Total Shareholders' Deficit | −7 | −6 | −507,658 | −22,108 | |
| Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption, and Shareholders' Deficit | 182 | 175 | 2,021 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Net Income (loss) | 6 | −71,012 | −485,550 | |
| Payment of operation costs through promissory note | — | 4,719 | — | |
| Dividends earned on marketable securities held in Trust Account | −7 | −125,346 | — | |
| Prepaid expenses | 202,381 | −212,059 | 2,000 | |
| Due to Sponsor | 104,762 | 2,000 | — | |
| Accounts payable and accrued expenses | 29,008 | −449,748 | 1,006 | |
| Net cash used in operating activities | −608,387 | −851,446 | −204 | |
| Investment of cash in Trust Account | — | −174 | — | |
| Net cash used in investing activities | — | −174 | — | |
| Proceeds from sale of Units, net of underwriting discounts paid | — | 169 | — | |
| Proceeds from sale of Private Placements Warrants | — | 7 | — | |
| Proceeds from promissory note - related party | 200,000 | 406,540 | — | |
| Repayment of promissory note - related party | — | −800,000 | — | |
| Payment of offering costs | — | −218,941 | — | |
| Net cash provided by financing activities | 200,000 | 176 | — | |
| Net Change in Cash | −408,387 | 436,153 | −204 | |
| Offering costs included in accrued offering costs | — | 495,872 | 5,830 | |
| Deferred offering costs paid through promissory note - related party | — | 41,241 | 88,500 | |
| Deferred underwriting fee | — | 6 | — | |
| Offering costs charged to additional paid-in capital | — | 756,054 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Translational Development Acquisition Corp.'s CIK number?
Translational Development Acquisition Corp.'s SEC CIK number is 0001926599 (1926599). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Translational Development Acquisition Corp.'s SEC filings?
All of Translational Development Acquisition Corp.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.